Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
数字之外:4位分析师讨论y-mabs therapeutics股票
In the latest quarter, 4 analysts provided ratings for Y-mAbs Therapeutics (NASDAQ:YMAB), showcasing a mix of bullish and bearish perspectives.
在最新的季度里,有4位分析师为y-mabs therapeutics(纳斯达克:YMAB)提供了评级,展示了看好和看淡观点的混合。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中,您将找到他们最近的评级摘要,揭示了过去30天内情绪的变化,并将它们与前几个月进行比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.0, along with a high estimate of $23.00 and a low estimate of $20.00. This upward trend is apparent, with the current average reflecting a 1.52% increase from the previous average price target of $21.67.
分析师们提供了更深入的见解,已经设定了12个月的价格目标,显示平均目标为22.0美元,高估值为23.00美元,低估值为20.00美元。这种上升趋势是明显的,当前的平均值反映了与之前的平均目标价格21.67美元相比增加了1.52%。
Diving into Analyst Ratings: An In-Depth...
深入探讨分析师...
登录免费看全文
登录/注册